Table 3.
The association of combination therapy and plasma IFX concentrations with the risk of development of detectable Antibodies To Infliximab (n=183) a
| Univariate | Multivariate b | ||||
|---|---|---|---|---|---|
| event/N | HR(95%CI) | P value | HR(95%CI) | P value | |
| Age | 1.10(0.98,1.23) | 0.11 | 1.17(1.01,1.37) | 0.04 | |
| Female vs male | 1.13(0.49,2.60) | 0.77 | 0.62(0.24,1.61) | 0.33 | |
| Body Mass Index | 1.09(1.01,1.18) | 0.03 | 1.08(0.99,1.18) | 0.08 | |
| CRP | 0.19(0.01,2.88) | 0.23 | 0.05(0.002,1.47) | 0.08 | |
| Albumin | 0.51(0.13,1.94) | 0.32 | 0.20(0.04, 1.11) | 0.07 | |
| Type of IBD | |||||
| Crohn's Disease | 19/155 | 1.00 | 1.00 | ||
| Ulcerative Colitis or Indeterminate Colitis | 5/28 | 2.13(0.78,5.80) | 0.14 | 1.28(0.43,3.88) | 0.66 |
| Combination therapy | |||||
| Never | 5/21 | 1.00 | 1.00 | ||
| Prior | 7/90 | 0.27(0.08,0.88) | 0.03 | 0.10(0.02,0.44) | 0.002 |
| Current | 12/72 | 0.49(0.17,1.43) | 0.19 | 0.21(0.05,0.78) | 0.02 |
| Infliximab<5.0 μg/mL | |||||
| No | 21/145 | 1.00 | 1.00 | ||
| Yes | 3/38 | 0.63(0.19, 2.11) | 0.45 | 0.46(0.11,1.90) | 0.28 |
a
The analysis was conducted using Cox proportional hazard model, those (n=36) with detectable Antibodies To Infliximab at enrollment were excluded from the analysis
b
Adjusted for Age (continuous), sex (male vs. female), Body Mass Index (continuous), CRP, albumin levels, and IBD disease types